• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Royalty Pharma Plc Cl A (NQ: RPRX )

    28.17 -0.37 (-1.30%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Royalty Pharma Plc Cl A

    < Previous 1 2 3 4 5 6 Next >
    Royalty Pharma Reports Q4 and Full Year 2022 Results
    From Royalty Pharma plc
    Via GlobeNewswire
    Preview: Royalty Pharma's Earnings
    Via Benzinga
    Royalty Pharma to Present at Upcoming Investor Conferences
    From Royalty Pharma plc
    Via GlobeNewswire
    February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
    The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... 
    Via Benzinga
    Ominous Death Cross Forms On Royalty Pharma's Chart
    Via Benzinga
    Looking Into Royalty Pharma's Return On Capital Employed
    Via Benzinga
    Expert Ratings for Royalty Pharma
      Within the last quarter, Royalty Pharma (NASDAQ:RPRX) has observed the following analyst ratings: 
    Via Benzinga
    Five Best And Worst Performing Healthcare Stocks In December 2022
    Multiple factors are expected to help the healthcare industry overcome inflationary pressures. If you are looking to invest in this sector, then to help you select, here are the five best and worst... 
    Via Talk Markets
    Royalty Pharma To Announce Fourth Quarter And Full Year 2022 Financial Results On February 15, 2023
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma Highlights Accomplishments and Provides Business Update at 41st Annual J.P. Morgan Healthcare Conference
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma: Q2 Earnings Insights
      Royalty Pharma (NASDAQ:RPRX) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
    Via Benzinga
    Royalty Pharma Announces Dividend Increase
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 9
    From Royalty Pharma plc
    Via GlobeNewswire
    6 Stocks Warren Buffett Completely Exited in 2022
    Despite being an active buyer this year, Buffett's company Berkshire Hathaway also sold several of its holdings as it repositioned its portfolio. 
    Via The Motley Fool
    Royalty Pharma Announces Expansion of Senior Leadership Team
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma Agrees to Acquire Royalty Interest in Olpasiran From Arrowhead for $250 million and Future Milestones
    From Royalty Pharma plc
    Via GlobeNewswire
    Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Royalty Pharma Reports Third Quarter 2022 Results
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma to Announce Third Quarter 2022 Financial Results on November 8, 2022
    From Royalty Pharma plc
    Via GlobeNewswire
    If You Own These 3 Growth Stocks, You Might Want to Rethink Your Position
    There may be more trouble on the horizon for these stocks than most investors are seeing right now. 
    Via The Motley Fool
    Royalty Pharma Declares Fourth Quarter 2022 Dividend
    From Royalty Pharma plc
    Via GlobeNewswire
    Jim Cramer Likes This Biotechnology Stock: 'It's Not Big, But It's Not Bad'
    On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Royalty Pharma plc (NASDAQ: RPRX) and will stick with it. "It’s not big, but it’s not bad," he added. 
    Via Benzinga
    Royalty Pharma Announces Expansion of Leadership Team
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma Announces R&D Funding Collaboration With Merck
    Novel collaboration structure supports pipeline innovation 
    From Royalty Pharma plc
    Via GlobeNewswire
    Theravance Outlines $250M Capital Return Program; To Repurchase GSK's Entire Holdings
    Via Benzinga
    Royalty Pharma's Return On Capital Employed Insights
    Pulled from Benzinga Pro data, Royalty Pharma (NASDAQ:RPRX) posted Q2 earnings of $491.60 million, an increase from Q1 of 283.81%. Sales dropped to $535.96 million, a 4.63% decrease between quarters. 
    Via Benzinga
    Warren Buffett's Berkshire Takes Another Bite Of Apple, Boosts Energy Holdings, Cashes Out Of Verizon: What 13F Filing Reveals
    Warren Buffett-owned Berkshire Hathaway, Inc.’s (NYSE: BRK-A) (NYSE: BRK-B) portfolio saw some noteworthy and a few other nominal changes in the second quarter, according to the company's 13F filing. 
    Via Benzinga
    Jim Cramer Shares His Takes On First Solar, Royalty Pharma And More
    On CNBC’s "Mad Money Lightning Round," Jim Cramer said Royalty Pharma PLC (NASDAQ: RPRX) is going higher. "Hold on to it." 
    Via Benzinga
    < Previous 1 2 3 4 5 6 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.